To sum up, for advanced NSCLC patients with EGFR mutations, second-line treatment with almonertinib plus chemotherapy significantly improved PFS compared with almonertinib alone without a significant increase in adverse events, providing efficacy and safety. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.